Skip to content
ABOUT
AUTHOR GUIDELINES
AUTHORS/EDITORS
SUBSCRIPTIONS
CONTACT US
MY ACCOUNT
Facebook
Twitter
LinkedIn
Instagram
HOME
JOURNALS
ARTICLES IN PRESS
PSYCHOPHARMACOLOGY BULLETIN
FULL ISSUE STACKED PDFs
T.E.N.
MENTAL FITNESS
PSI
ONCOLOGY SPECTRUMS
PROJECTS
JOURNAL SUPPLEMENTS
PHYSICIAN ACADEMY SERIES
POCKET REFERENCE GUIDES
TEACHING MONOGRAPHS
MEDWORKS REPRINT SERIES
RESOURCES
PSYCHOTROPICS A-Z
PSYCHOTROPIC PRESCRIBING INFORMATION
PSYCHOTROPIC DOSAGE RANGES
PSYCHOPHARMACOLOGY 101
PSYCHIATRIC RATING SCALES
NEWS
WE KNOW PSYCHIATRY
FEATURED ARTICLES
×
Home
/
Larry Alphs, MD, PhD: Asenapine in the Treatment of Negative Symptoms of Schizophrenia: Clinical Trial Design and Rationale
Larry Alphs, MD, PhD: Asenapine in the Treatment of Negative Symptoms of Schizophrenia: Clinical Trial Design and Rationale
$
30.00
Add to cart
Want a discount? Become a member by purchasing
Psychopharmacology Bulletin Subscription - Individual
!
Categories:
Psychopharmacology Bulletin
,
VOL 40 No. 2 Articles
Tags:
asenapine
,
clinical-trial
,
john-panagides
,
larry-alphs
,
md
,
ms
,
negative-symptoms
,
phd
,
schizophrenia
,
scott-lancaster
,
study-design
Description
Description
Larry Alphs, MD, PhD
ORIGINAL RESEARCH
Asenapine in the Treatment of Negative Symptoms of Schizophrenia: Clinical Trial Design and Rationale
Larry Alphs, MD, PhD, John Panagides, PhD, and Scott Lancaster, MS
Share On Facebook
Tweet This Product
Pin This Product
Email This Product
Related products
Physical Activity Diminishes Symptomatic Decline in Chronic Schizophrenia: A Systematic Review
$
30.00
Add to cart
Details
Ethical Issues in Schizophrenia: Considerations for Treatment and Research
$
30.00
Add to cart
Details
Calgary Depression Scale for Schizophrenia (CDSS)
$
0.00
Add to cart
Details
Nienke Dekker, MD: Cessation of Cannabis Use by Patients with Recent-Onset Schizophrenia and Related Disorders
$
30.00
Add to cart
Details
